Fc-relaxin fusion protein (TX45)

Protein / enzyme therapeutic

Also known as TX000045

Earlyevidence

Evidence outlook

Pulmonary Hypertension due to Left Heart Disease: mid-stage studies underway, no completed readout

In Pulmonary Hypertension due to Left Heart Disease, Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. Studies in other indications have read out; see the trials and Regulatory events below.

Also in development:Pulmonary Hypertension Associated with Interstitial Lung Disease · Phase 2

Company guidance: topline data expected January 2027 (Tectonic Therapeutic, 5 Nov 2026). “Topline results from the APEX Phase 2 clinical trial of TX45 in pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-HFpEF”) are anticipated by the end of January 2027” Source ↗

Company guidance: interim data expected second half of 2027 (Tectonic Therapeutic, 5 Nov 2026). “Dosed first patient in the ALPINE Phase 2a clinical trial of TX45 in pulmonary hypertension associated with interstitial lung disease (“PH-ILD”) in October 2026, with interim topline results expected in the second half of 2027” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Pulmonary Hypertension Associated with Interstitial Lung Disease
Pulmonary Hypertension due to Left Heart Disease

Competitive landscape

Other Relaxin receptor (RXFP1) / relaxin drugs

Pexerelgon, R2R01. Compare all 3 Relaxin receptor (RXFP1) / relaxin drugs

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Pulmonary Hypertension Associated with Interstitial Lung Disease: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Fc-Relaxin Fusion Protein (TX45): this drugPhase 2Protein / enzyme therapeuticRelaxin receptor (RXFP1) / relaxinnot yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso DPI)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT02630316: Change in peak 6-minute walk distance from baseline to week 16: inhaled treprostinil median +6.0 m vs placebo -9.0 m (n=163 each); Hodges-Lehmann difference 21.0 m (95% CI 7.0 to 37.0), p=0.0043 (CT.gov posted results).
Treprostinil (Yutrepia, Liquidia)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
MosliciguatPhase 3Small moleculeSoluble guanylate cyclasenot yet gradedNo reviewed efficacy summary in this indication
Treprostinil (L606)Phase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
LAM-001Phase 2Small moleculemTOR (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
MirivadelgatPhase 2Small moleculeALDH2not yet gradedNo reviewed efficacy summary in this indication
Pexerelgon
Phase 2(overall)
Small moleculeRelaxin receptor (RXFP1) / relaxin
Partial signal(overall)
No reviewed efficacy summary in this indication
R2R01
Phase 2(overall)
PeptideRelaxin receptor (RXFP1) / relaxin
Weak signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Fc-relaxin fusion protein (TX45) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Phase 2Pulmonary Hypertension due to Left Heart DiseaseActive not recruiting
Est. primary completion 2026-11-24 · NCT06616974 · CT.gov ↗
What to watch
2027 (1)
November 2027 (1)
Phase 2Pulmonary Hypertension Associated with Interstitial Lung DiseaseRecruiting
Est. primary completion 2027-11-21 · NCT07473700 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 October 2025Topline resultTX45 Phase 1b Part B topline results in PH-HFrEF